Literature DB >> 32941403

Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients.

Yachao Liu1, Guanyun Wang1,2, Hongkai Yu3, Yue Wu4, Mu Lin4, Jiangping Gao2, Baixuan Xu1.   

Abstract

OBJECTIVES: This study aimed to compare the diagnostic performance of F-DCFPyL and 2-deoxy-2-[F]fluoro-D-glucose (F-FDG PET/computed tomography in the restaging of clear cell renal cell carcinoma after nephrectomy.
METHODS: In this retrospective study, a total of 15 patients with suspected local recurrence of clear cell renal cell carcinoma or metastasis after surgery underwent both F-DCFPyL and F-FDG PET/computed tomography. A systematic comparison of the maximum standardized uptake value and the target to background ratio was carried out between the lesions detected by the two tracers.
RESULTS: A total of 42 lesions were detected either by F-DCFPyL PET/computed tomography or by F-FDG PET/computed tomography. F-DCFPyL PET/computed tomography, but not F-FDG PET/computed tomography, accurately distinguished the two local recurrence from four postoperative changes. The remaining 36 lesions were soft tissue (14) and bone lesions (22); all 36 lesions were detected by F-DCFPyL PET/computed tomography while only 10 (10/14) soft tissue lesions and 12 (12/22) bone lesions were detected by F-FDG PET/computed tomography. The higher detection rate of soft tissue lesions using F-DCFPyL PET/computed tomography was not statistically significant (P = 0.125); however, F-DCFPyL PET/computed tomography was statistically better (P = 0.002) at detecting bone lesions. The average maximum standardized uptake value and target to background ratio of F-DCFPyL were significantly higher than that of F-FDG for soft tissue lesions (maximum standardized uptake value P = 0.005; target to background ratio P = 0.028) and bone lesions (maximum standardized uptake value P = 0.001; target to background ratio P = 0.001).
CONCLUSIONS: Our preliminary results indicated that F-DCFPyL PET/computed tomography is superior to F-FDG PET/computed tomography for the detection of local recurrence at both the surgical site and in bone metastasis while the tracers are comparable in the detection of soft tissue metastases.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32941403     DOI: 10.1097/MNM.0000000000001285

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  3 in total

Review 1.  PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature.

Authors:  Stijn Muselaers; Selcuk Erdem; Riccardo Bertolo; Alexandre Ingels; Önder Kara; Nicola Pavan; Eduard Roussel; Angela Pecoraro; Michele Marchioni; Umberto Carbonara; Laura Marandino; Daniele Amparore; Riccardo Campi
Journal:  J Clin Med       Date:  2022-03-25       Impact factor: 4.241

Review 2.  PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?

Authors:  Alessio Rizzo; Sara Dall'Armellina; Daniele Antonio Pizzuto; Germano Perotti; Luca Zagaria; Valerio Lanni; Giorgio Treglia; Manuela Racca; Salvatore Annunziata
Journal:  Cancers (Basel)       Date:  2022-08-21       Impact factor: 6.575

3.  Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma.

Authors:  Cristian Udovicich; Jason Callahan; Mathias Bressel; Wee Loon Ong; Marlon Perera; Ben Tran; Arun Azad; Shankar Haran; Daniel Moon; Sarat Chander; Mark Shaw; Renu Eapen; Jeremy Goad; Nathan Lawrentschuk; Declan G Murphy; Michael Hofman; Shankar Siva
Journal:  Eur Urol Open Sci       Date:  2022-08-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.